The Phase I/II Clinical Trials Committee of the Cancer Research Campaign (CRC) was established in 1980 with the remit of expediting the early clinical evaluation of novel cancer therapeutics. In order to meet this objective, resources and facilities for the synthesis and formulation of new agents were made available, and through the Committee a network of phase I and phase II clinical investigators was established. In addition, it was recognized that safe, yet rapid, preclinical toxicology protocols would also be required if compounds were to progress efficiently into clinical trials. In designing the preclinical toxicology protocols, note was taken of a number of retrospective reviews which indicated that one-tenth of the mouse LD 10 (the dose lethal to 10% of mice treated), when doses are expressed on the basis of surface area (i.e. mg m -2 ), represents a safe phase I trial starting dose (Freireich et al, 1966; Homan, 1972; Goldsmith et al, 1975; Penta et al, 1979; Rozencweig et al, 1981) . More recent experience has largely confirmed the safety of selecting starting doses for phase I trials on the basis of the mouse toxicology data (Grieshaber and Marsoni, 1986; Penta et al, 1992; Arbuck et al, 1996) . In practise, however, in many countries a non-rodent species, usually the dog, is still routinely used in preclinical toxicology studies with cancer therapeutics.
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The preclinical toxicology protocols developed by the CRC, in conjunction with the European Organisation for Research and Treatment of Cancer (EORTC), took into account the accumulating data on the reliability of the mouse as a predictor of safe phase I clinical trial starting doses, and deliberately restricted studies to rodent-only investigations (Joint Steering Committee of the EORTC and CRC, 1990) . In brief, these protocols included determination of the MTD/LD 10 (maximum tolerated dose/dose lethal to 10% of treated animals) in mice following intraperitoneal (i.p.), intravenous (i.v.) and, where appropriate, oral (p.o.) administration. Haematology, histopathology and bone marrow cytology were performed for up to 28 days after a single dose of the agent at a dose close to the MTD/LD 10 , and after repeated dosing, usually daily for 5 days every week for 4 weeks. Lastly, the haematology, histopathology and bone marrow cytology studies were repeated in rats treated daily for 5 days every week for 4 weeks with onetenth of the mouse LD 10 , doses again being expressed as mg m -2 . The latter experiment was performed to check the safety of the proposed phase I trial starting dose in a second species, in an analogous manner to the use of the dog (Grieshaber and Marsoni, 1986 Summary Preclinical toxicology studies are performed prior to phase I trials with novel cancer therapeutics to identify a safe clinical starting dose and potential human toxicities. The primary aim of this study was to evaluate the ability of rodent-only toxicology studies to identify a safe phase I trial starting dose. In addition, the ability of murine studies to predict the quantitative and qualitative human toxicology of cancer therapeutics was studied. Data for 25 cancer drugs were collated for which the preclinical and clinical routes and schedules of administration were either the same (22/25), or closely matched. The maximum tolerated dose/dose lethal to 10% of mice (MTD/LD 10 ) was identified for 24 drugs, and in patients the maximum administered dose (MAD) was associated with dose-limiting toxicity (DLT) in initial clinical trials with 20 compounds. In addition, for 13 agents, the toxicity of the drug at one-tenth the mouse MTD/LD 10 was also investigated in rats, following repeated administration (20 doses). A phase I trial starting dose of one-tenth the mouse MTD/LD 10 (mg m -2 according to standards of Good Laboratory Practice (GLP), and used only male animals unless the drug was intended for human use in females or if there were known sex differences, in which case the most sensitive sex was used.
Recently, in the light of extensive experience within the CRC and EORTC, these rodent-only protocols have been revised (Burtles et al, 1995) . Specifically, the protocols now focus on the use of only clinically relevant schedules, doses (MTD and below) and routes of administration (i.v. or p.o.) . The emphasis in these revised protocols is on compound-specific toxicology, in order to both increase the clinical relevance of the results obtained and reduce the number of animals required. In addition, studies in rats now repeat directly those in mice to address the need for studies in two species and which, if either, of the two rodent species is more predictive of the subsequent human experience.
As of January 1998, the CRC had taken 44 novel cancer therapeutics, in which a small molecule drug forms all or part of the therapy, into phase I trial, i.e. this figure excludes antibody-alone and gene-based therapeutics. Of these 44 therapies, three were multi-component, i.e. CMDA or ZD2767 CPG2-A5B7 antibodydirected enzyme prodrug therapies (ADEPT) and PSC833-etoposide treatment (multidrug resistance modulation); five were anti-endocrine agents (4-hydroxyandrostenedione, abiraterone acetate (CB7630), idoxifene, pyridoglutethimide, zindoxifene); and for seven agents the phase I trial starting dose was derived from prior human experience in non-CRC studies (amsalog, 4-hydroxyanisole, eicosapentaenoic acid, D-limonene) or canine data (AG2034, CT2584, phyllanthoside). Four of the remaining 29 therapies are still under phase I investigation (AMD473, DMXAA, PK2 and SPAG), leaving 25 agents for which comparisons of preclinical rodent toxicology and clinical phase I trial results can be performed (Table 1) .
The primary aim of the current study was to assess retrospectively the safety of using rodent-only toxicology in selecting phase I trial starting doses. In addition, this study has allowed: 1. A comparison of the quantitative toxicity of novel agents in mice and humans; i.e. a comparison of the MTD/LD 10 in mice and the MTD or MAD (maximum administered dose) in patients. 2. An analysis of the qualitative toxicology of compounds in mice and in humans; specifically, the ability of murine studies to predict dose-limiting and other human toxicities. 3. An evaluation of the utility of results from early clinical trials in rapidly optimising schedules for phase II (therapeutic) evaluation.
MATERIALS AND METHODS
The 25 drugs included in the current analysis are listed in Table 1 . Table 1 also summarizes the properties of the compounds, the general class to which each compound belongs and references to the reports describing the phase I clinical trials. The clinical studies were all approved by, and performed under the auspices of, the CRC Phase I/II Clinical Trials Committee. In addition, each trial was approved by the relevant local ethics committee (institutional review board). Preclinical toxicology studies were performed according to the protocols previously published (Joint Steering Committee of the EORTC and CRC, 1990; Burtles et al, 1995) , and the full reports are held on file at the Drug Development Office, CRC, London, UK. Experiments were conducted according to local animal welfare regulations and were covered by a UK Home Office project licence.
RESULTS

Preclinical toxicology studies
The quantitative preclinical murine toxicology data on the 25 compounds studied are given in Table 2 . The route and schedule of administration were those used in initial clinical studies with only three exceptions: etoposide phosphate and C6G mustard -where the clinical route was i.v. and not i.p.; and DACA -where the clinical schedule was daily ×3 and not daily ×5. With the exception of four drugs (BZQ, mitozolomide, JM216, C6G mustard), the preclinical toxicology studies were performed according to GLP. Table 2 also lists the murine MTD/LD 10 data, the phase I trial starting doses and the ratios of the phase I trial starting dose to the mouse MTD/LD 10 . In one case, temozolomide, a murine MTD/LD 10 , could not be defined because of the limited solubility of the drug in the i.v. formulation (20% v/v dimethyl sulphoxide (DMSO) in saline). In all other cases, the MTD/LD 10 was defined, with a very broad range of potencies being observed (0.037-791 mg kg -1 day -1
). Excluding temozolomide, the median (range) ratio of the phase I trial starting dose to the mouse MTD/LD 10 was 0.1 (0.01-0.83), and for 17/24 drugs the starting dose was within the range 5-15% of the mouse MTD/LD 10 . For the other seven drugs there was a greater than 50% deviation from one-tenth of the mouse MTD/LD 10 as the phase I starting dose. The reasons for these deviations were as follows: clomesone (starting dose: MTD/LD 10 ratio = 0.01), due to a transcriptional error in the clinical protocol; mitozolomide (0.04), because of the clinical toxicities of other chloroethylating agents; etoposide phosphate (0.83), due to prior experience with etoposide; 1069C85 (0.02), and elactocin (0.01), because of marked toxicity in rats following repeated administration at one-tenth of the mouse MTD/LD 10 (see below); FAA (0.49), following prior experience with LM985; and trimelamol (0.04), due to prior experience with methylmelamines.
The qualitative murine toxicology data for the 25 drugs studied are summarized in Table 3 . Three general categories of toxicology were recorded: clinical, macroscopic tissue pathology/histopathology and haematology/chemical pathology. In the case of chemical pathology, studies were not performed with all the drugs investigated as the requirement for such tests has only recently been introduced (Burtles et al, 1995) . Furthermore, in describing clinical effects, non-specific signs such as piloerection and hypokinesia have not been reported. In addition to listing the toxicities observed with each drug, Table 3 also indicates the dose level at which the toxicity was observed. Although in the majority of cases the effects were observed at or below the i.v./p.o./i.p. MTD/LD 10 , toxicities were in some cases only observed at higher dose levels or following repeated administration.
For 13 compounds, a repeat-dose i.p. toxicity study was performed in rats with five daily doses of one-tenth the mouse MTD/LD 10 being given every week for 4 weeks, i.e. 20 doses in total. As previously described (Joint Steering Committee of the EORTC and CRC, 1990), these studies were performed to confirm the safety of the proposed phase I trial starting dose in a second species. The drugs studied in rats were CB10-277, clomesone, temozolomide, didox, MZPES, CI941, etoposide phosphate, 1069C85, amphethinile, elactocin, LM975, SDZ 62-434 and trimelamol. In the case of temozolomide, one-tenth of the MAD and not MTD was used, as the latter could not be defined in mice due to the limited solubility of the drug in the i.v./i.p. vehicle (20% v/v DMSO in saline). With two exceptions, the only effects seen in rats following repeated dosing were minor reversible haematological changes (7/13), decreases in the rate of body weight gain (4/13) and testicular effects (2/13). However, for two compounds, 1069C85 and elactocin, there was significant toxicity following repeated administration to rats. With 1069C85 there was significant necrosis of the gastrointestinal tract and atrophy of lymphoid tissues at one-tenth the mouse MTD/LD 10 , and with elactocin neither one-tenth nor one-hundreth of the mouse MTD/LD 10 were tolerated by rats on repeated dosing. On the basis of these rat data, the phase I trial starting doses of 1069C85 and elactocin were reduced to less than the one-tenth mouse MTD/LD 10 ( Table 2) .
Initial phase I trial results
The quantitative details of the phase I trials initially performed with the 25 drugs are presented in Table 4 . The median number of patients in the trials was 34, ranging from seven (RSU1069) to 64 (MZPES), and the median number of dose levels was eight, ranging from three (RSU1069) to 19 (clomesone). The dose escalation schema used in the phase I trials, which included arithmetic and 'modified Fibonacci' approaches, are given in the references cited in the Table 1. Table 4 also lists the human MAD, and for 20/25 drugs dose-limiting toxicity (DLT) was observed at or below the MAD. For the remaining five drugs, the initial clinical study was stopped before DLT was observed, either because administration was changed to an alternative route (temozolomide) or schedule (JM216, AG337), or because drug supplies were exhausted (C6G mustard and SDZ 62-434). Results of the subsequent clinical studies with temozolomide, JM216 and AG337 are discussed below. Table 4 also compares the human MAD and the mouse MTD/LD 10 , and gives the ratios of these two values. With the three exceptions indicated previously, i.e. DACA, etoposide phosphate and C6G mustard, the murine and clinical data are directly comparable in terms of route and schedule of administration. A comparison of the human MAD and the murine MTD/LD 10 values is shown graphically in Figure 1 , and for the 20 drugs where DLT was observed at the human MAD, the median ratio of the human MAD to the mouse MTD/LD 10 was 2.6, with a range of 0.2-16. For the same 20 drugs, the median ratio of the phase I trial starting dose to the eventual MAD was 35, ranging from 2.3 to 160, i.e. DLT was not observed at the starting dose for any these drugs. By definition, for the five drugs where DLT was not observed in the phase I trial, the phase I trial starting dose was also safe. Furthermore, for the five drugs (clomesone, mitozolomide, 1069C85, elactocin and trimelamol), where for various reasons (see above) the phase I trial starting doses were less than the onetenth the mouse MTD/LD 10 , DLT would not have been observed even if one-tenth the mouse MTD/LD 10 had been used. This latter point is illustrated by the data points all being above the broken line in Figure 1 . The qualitative human toxicology data for the 25 compounds studied are presented in Table 5 . Toxicities are distinguished as being either dose-limiting or not on the basis of the phase I trial reports (see Table 1 ). By comparing the data in Table 5 with those in Table 3 , the ability of the preclinical murine studies to predict each human toxicity was determined. In comparing the human and murine data, it was recognized that a number of the human toxicities were either not evaluable or not evaluated in the preclinical experiments. The non-evaluable toxicities were nausea and vomiting, malaise/asthenia, flushing, fever/rigors, hypotension, headache, chest pain, hypersensitivity, rash, pain and myalgia. For the 20 drugs where DLT was observed, 22 toxic events were described as being dose-limiting. In the case of amphethinile, although DLT was reached, the exact nature of the DLT was not defined. The most common DLTs were haematological (7/22), nausea and vomiting (5/22) and neurotoxicity (3/22), the remaining DLTs only being reported on one occasion each. Of the human DLTs that were evaluated in the murine studies (12/22), 11 were correctly predicted, i.e. haematological seven, neurological three and mucositis one. Didox was the only drug where the human dose-limiting end organ, the liver, was studied in the preclinical experiments but toxicity was not observed. In total there were 78 other or non-DLTs reported, the most common being nausea and vomiting (18/78), diarrhoea (10/78), haematological (8/78), alopecia (7/78), malaise/asthenia (5/78), mucositis (4/78), hepatic (4/78) and neurological (4/78). Other toxicities occurred with an incidence of < 4 in 78 (i.e. < 5%). For the more common non-DLTs that were evaluated in the murine studies, the ability of the preclinical experiments to predict the human observations was as follows: diarrhoea 7/10, haematological 7/7, alopecia 2/6, mucositis 3/4, neurological 3/4 and hepatic 1/4.
Subsequent phase I trial results
On the basis of the initial phase I trial results presented in Tables 4  and 5 , 11 compounds were subject to a total of 13 further dose escalation studies in an attempt to optimize the dose, route and/or schedule of administration prior to therapeutic evaluation. As shown in Table 6 , these additional studies involved a median of 32 patients per trial (range 6-42) and a median of 5 (range 3-12) dose levels. Importantly, the median ratio of the starting to the maximum dose administered was only 2.8 (range 1.6-56), i.e. a much smaller ratio than in the initial clinical trials (Table 4) .
DISCUSSION
The primary aim of the studies described in this paper was to evaluate the safety of initiating phase I trials with novel cancer therapeutics on the basis of rodent-only toxicology studies. Specifically, for all 24 drugs for which a mouse MTD/LD 10 was defined, one-tenth of this dose was, or would have been, safe in humans. With two compounds DLT was observed in patients at doses clearly less that the mouse MTD/LD 10 , i.e. RSU1069 (DLTnausea and vomiting) and elactocin (DLTs -asthenia/malaise and nausea/vomiting). However, for both drugs the DLTs were not evaluable in mice. Although for seven drugs the phase I trial starting dose was not in fact one-tenth the mouse MTD/LD 10 , or close to it, had one-tenth the mouse MTD/LD 10 been used DLT would not have been encountered. Lastly, in the case of three compounds (AG337, flavone acetic acid and penclomidine) dog toxicology data were available at the time phase I trials were initiated; however, in all three cases the mouse was the most sensitive species and hence the phase I trial starting dose was based on the murine data.
The results reported here are in agreement with earlier retrospective reviews of the relationships between preclinical and clinical toxicology data (Freireich et al, 1966; Homan, 1972; Goldsmith et al, 1975; Penta et al, 1979; Rozencweig et al, 1981) as well as, in the main, more recent studies (Grieshaber and Marsoni, 1986; Penta et al, 1992; Arbuck et al, 1996) . In these latter more recent reviews, which in some cases included certain of the drugs described here, a small number of drugs were identified where initiation of phase I trials at one-tenth of the mouse MTD/LD 10 would have exceeded the human MTD. The three most clear-cut instances were fludarabine (Grieshaber and Marsoni, 1986) , tallimustine (Dent and Eisenhauer, 1996) and LY231514 (Dent and Eisenhauer, 1996) . Both fludarabine and LY231514 are antimetabolites, and interspecies differences in the whole animal and cellular pharmacology of this class of drugs is well recognized. Of the 25 drugs Table 6 Details of subsequent phase I trials performed using results from initial studies (see Tables 4 and 5 studied by the CRC, three were antimetabolites (AG337, didox and MZPES) and for all three agents the murine toxicology safely identified a safe phase I trial starting dose. However, it should be noted that these three drugs are direct-acting antimetabolites, i.e. unlike classical antifolates and base/nucleoside analogues, they are not subject to intracellular metabolic activation. As such, the three antimetabolites studied here may not be representative of the drug class as a whole. Particular care needs to be taken in selecting phase I trial starting doses with antimetabolites, especially when the compound is known to undergo metabolic activation. In general, the use of two species in preclinical toxicology studies is recommended in order to identify and compensate for marked interspecies differences. Most authorities require studies in one rodent and one non-rodent species, the non-rodent species usually being the dog. In reviewing data on 27 phase I trials with 17 new cytotoxic drugs, Dent and Eisenhauer (1996) concluded that dog toxicology data had appropriately influenced the choice of the phase I trial starting dose on three of the six occasions it was used (topotecan, LY231514, tallimustine). However, in reviewing data collated by Verweij (1996) , Arbuck noted that the rat may also be able to safely identify a phase I trial starting dose, even when there were marked species differences in toxicology (Arbuck, 1996) . In the current study, rat toxicology studies were only performed on a sub-set of 13 compounds, and then solely to check the safety of the proposed phase I trial starting dose, i.e. one-tenth the mouse MTD/LD 10 , when given by repeated administration. Hence a comparison of the relative abilities of mouse and rat toxicology studies to predict quantitative and qualitative human toxicology data cannot be made on the basis of the results presented here. Recent modifications to the CRC/EORTC protocols will allow a direct comparison of mouse, rat and human toxicology data (Burtles et al, 1995) , and results are currently being accumulated.
In addition to the primary aim of determining the safety of onetenth of the mouse MTD/LD 10 as a phase I trial starting dose, this study has allowed a comparison of the quantitative and qualitative murine and human toxicologies for a range of drugs with widely varying structures, mechanisms of action and potencies. A comparison of the human MAD and the mouse MTD/LD 10 , for drugs where clinical DLT was achieved, revealed a median ratio of 2.6 (range 0.2-16), a value and a range similar to those reported previously (Freireich et al, 1966; Homan, 1972; Goldsmith et al, 1975; Penta et al, 1979; Rozencweig et al, 1981; Grieshaber and Marsoni, 1986; Penta et al, 1992; Arbuck et al, 1996; Dent and Eisenhauer, 1996) . With respect to the ability of the mouse to predict the qualitative nature of toxicities subsequently observed in humans, the data are again in agreement with earlier comparisons. Thus, haematological, neurological and antiproliferative-gastrointestinal human toxicities were predicted in most cases by the murine studies. Whilst it is recognized that mice, and to a lesser extent rats, do not allow investigations of the extent and sophistication possible in larger animals, the experience of the CRC is that this does not compromise patient safety, and that toxicities which more frequently become dose-limiting in human trials are detected in murine studies. In addition to systematically evaluating the rat in preclinical toxicology studies, recent revisions to the CRC/EORTC protocols (Burtles et al, 1995) include the routine use of chemical pathology studies, and these may help to identify less common side effects, e.g. renal, hepatic and cardiac toxicities, more reliably.
As noted by Dent and Eisenhauer (1996) , phase I trials can be subdivided into those representing the first human experience with the drug, and those based on prior clinical data. In the current analysis, a similar distinction was made and the results obtained indicate that, once human data are available, subsequent clinical trials are in most cases conducted over a much smaller dose range, a median of 2.8 for the subsequent trials in Table 6 versus 35 for  the initial trials listed in Table 4 . Although clinical responses in phase I trials are rare (Estey et al, 1986; Decoster et al, 1990; Penta et al, 1992; Arbuck, 1996) , they are more frequent at doses close to the MTD/recommended phase II dose (Penta et al, 1992) , and hence it is important to minimize the number of patients treated in phase I trials at lower dose levels. From the data in Table 6 , it is apparent that one approach to reducing the number of patients treated at doses that are unlikely to be effective is to rapidly obtain initial clinical data and then optimize the human dose, route and schedule of administration.
In the studies described in this paper, a range of approaches to dose escalation were used and, for the initial clinical studies (Table  4) , the number of patients entered and dose levels required varied widely (median (range)), i.e. 34 (7-64) and 8 (3-19) respectively. Although it was not the aim of the current study to analyse the relative merits of the different dose escalation schemes used, the issues of dose escalation and phase I trial starting dose identification are intimately linked. Whilst the use of a 'homeopathic' phase I trial starting dose would invariably be safe, too conservative a starting dose can result in over lengthy dose escalation, time delays in starting therapeutic trials, the unnecessary use of clinical resources and large numbers of patients being treated at doses that are not even potentially therapeutic (Collins et al, 1986; Collins et al, 1990; Penta et al, 1992; Ratain et al, 1993; Simon et al, 1997) . On the basis of the data presented here, one-tenth of the mouse MTD/LD 10 as a phase I trial starting dose appears to be a satisfactory compromise between a dose that is safe, but too low, and one that is more likely to be therapeutic, but also toxic. Once the phase I trial has been safely initiated, the challenge of rapidly identifying a dose for therapeutic evaluation should focus on the use of innovative dose escalation approaches including the application of all available preclinical data, pharmacologically guided dosing, model-based study designs and the use of pharmacodynamic trialend points (Collins et al, 1986 (Collins et al, , 1990 EORTC Pharmacokinetics and Metabolism Group, 1987; O'Quigley and Chevret, 1991; Mick and Ratain, 1993; Ratain et al, 1993; Arbuck, 1996; Dent and Eisenhauer, 1996; Simon et al, 1997) . In order to expedite such innovative designs it is essential that pharmacokinetic and pharmacodynamic investigations are included in preclinical toxicology studies wherever possible.
In considering the results of the preclinical and clinical studies described in this paper, and their implications for the identification of new cancer treatments, it is important to recognize the stages of clinical drug development these preclinical studies are intended to facilitate. The aim of the original and revised CRC/EORTC toxicology protocols (Joint Steering Group of the EORTC and CRC, 1990; Burtles et al, 1995) was to allow the rapid yet safe introduction of new cancer drugs into phase I trials and, provided acceptable clinical toxicology and pharmacology are observed, phase II therapy studies. The CRC/EORTC toxicology protocols are therefore intended to facilitate the equivalent of a United States Food and Drug Administration Investigational New Drug application (FDA-IND). In discussing regulatory considerations relevant to the preclinical development of anticancer drugs, DeGeorge and colleagues have recently emphasized the important distinction between studies required for an FDA-IND and those required to support a New Drug Application (NDA) (DeGeorge et al, 1998) . In the design of toxicology studies to support an NDA, these authors recognized the need to take into account the proposed therapeutic indication, the outcome of early clinical development, the nature of toxicities seen in animals and in humans, and the projected duration of clinical treatment. Whilst it is envisaged that the preclinical toxicology protocols used by the CRC/EORTC should ultimately facilitate NDA-type clinical trials, these protocols are not seen as a substitute for the more detailed compound-specific toxicology studies that may be required for product registration.
Although, of necessity, the study described in this paper constitutes a retrospective analysis, given the need to accrue both preclinical and clinical data, it represents the prospective evaluation of rodent-only preclinical toxicity studies. As such, the original hypothesis that rodent-only toxicity studies can be used to identify safe phase I trial starting doses has been tested and proven, for the 25 drugs studied. Of the 25 drugs investigated the majority (15) were conventional cytotoxic drugs (i.e. alkylating agents, antimetabolites, topoisomerase inhibitors or tubulin binding agents; Table 1 ), and hence caution must be exercised in extrapolating from the current results to newer classes of agents acting by novel mechanisms, e.g. mitogenic signal transduction inhibitors, anti-angiogenic and antimetastatic agents. However, clinical experience with these newer classes of drugs is currently insufficient to allow firm recommendations as to the most relevant preclinical toxicology models to use, and hence the emphasis should be on compound-specific protocols in the first instance. Specifically, in the context of the current study, it is not possible to comment on the relative merits of rodent and non-rodent species. In general, with the development of agents designed to exploit specific tumour-associated molecular lesions, the issue of targetrelated versus target-unrelated toxicity is likely to assume greater importance. In designing preclinical studies to address this issue, the increasing availability of gene knockout mice may have an important role to play. For example, toxicities seen in mice lacking the gene for the drug target must, by definition, be unrelated to the proposed mechanism of the anti-tumour action of the drug. Studies with gene knockout animals are likely to be restricted to rodents for the foreseeable future, and hence are complementary to the rodent-only approach described here.
In summary, the experience of the CRC in the phase I evaluation of 25 novel cancer therapeutics has shown that 1/10th the mouse MTD/LD 10 represented a safe Phase I trial starting dose for every drug. With the exception of nausea and vomiting, which cannot be evaluated in rodents, the more common human DLTs (haematological and neurological toxicity) were reliably predicted by the murine studies. These data do not support the routine use of a non-rodent species in preclinical toxicology studies prior to initial clinical trials with anticancer treatments.
